Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotrectinib for TRK Fusion Pediatric Solid Tumors and Relapsed Acute Leukemias
NCT03834961Phase 2Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Oct 2019
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of larotrectinib in infantile fibrosarcoma (IFS), solid tumor and acute leukemia, sponsored by Children's Oncology Group. Primary endpoint: Objective Response Rate up to 5 years. Started Oct 2019; status: active, not recruiting.
02
Drugs
larotrectinib
03
Conditions
infantile fibrosarcoma (IFS)solid tumoracute leukemia
Beyond the preview
Go deeper on NCT03834961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834961.